Consequently, strategies aimed at inhibiting IBA or selectively blocking its interaction with ROCK1 present promising avenues for further investigation in the field of CRC immunotherapy, offering a novel therapeutic approach to overcome the challenges associated with immunotherapy resistance. The gene discussed is ROCK1; the disease is colorectal carcinoma.